89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer

…, TC Kwee, SG Elias, JA Gietema, SS Bohorquez… - Nature medicine, 2018 - nature.com
Programmed cell death protein-1/ligand-1 (PD-1/PD-L1) blockade is effective in a subset of
patients with several tumor types, but predicting patient benefit using approved diagnostics is …

Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease: two phase 3 randomized placebo-controlled trials

…, B Ostaszewski, SM Sanabria-Bohórquez… - JAMA …, 2022 - jamanetwork.com
Importance Alzheimer disease (AD), a neurodegenerative disease characterized by β-amyloid
plaques and τ tangles in the brain, represents an unmet medical need with no fully …

[PDF][PDF] The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake

…, BJ Musser, K Lu, J Yuan, SM Sanabria-Bohórquez… - Cell Metabolism, 2008 - cell.com
Cannabinoid 1 receptor (CB1R) inverse agonists are emerging as a potential obesity therapy.
However, the physiological mechanisms by which these agents modulate human energy …

Safety and efficacy of semorinemab in individuals with prodromal to mild Alzheimer disease: a randomized clinical trial

…, F Brunstein, M Blendstrup, SS Bohorquez… - JAMA …, 2022 - jamanetwork.com
Importance Neurofibrillary tangles composed of aggregated tau protein are one of the
neuropathological hallmarks of Alzheimer disease (AD) and correlate with clinical disease severity…

[PDF][PDF] Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults

…, H Bays, P Hollander, SM Sanabria-Bohórquez… - Cell metabolism, 2006 - cell.com
Neuropeptide Y (NPY) is a potent orexigenic neuropeptide, and antagonism of NPY Y1 and
NPY Y5 receptors (NPYxR) is considered a potentially important anti-obesity drug target. We …

Occipital activation by pattern recognition in the early blind using auditory substitution for vision

…, E Streel, A Robert, S Sanabria-Bohórquez… - Neuroimage, 2001 - Elsevier
This PET study aimed at investigating the neural structures involved in pattern recognition in
early blind subjects using sensory substitution equipment (SSE). Six early blind and six …

Phase I dose-escalation study of taselisib, an oral PI3K inhibitor, in patients with advanced solid tumors

…, TR Wilson, JA Ware, SM Sanabria Bohorquez… - Cancer discovery, 2017 - AACR
Taselisib is a potent and selective tumor growth inhibitor through PI3K pathway suppression.
Thirty-four patients with locally advanced or metastatic solid tumors were treated (phase I …

[18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor

…, K Van Laere, S Sanabria-Bohórquez… - Proceedings of the …, 2007 - National Acad Sciences
[ 18 F]MK-9470 is a selective, high-affinity, inverse agonist (human IC 50 , 0.7 nM) for the
cannabinoid CB1 receptor (CB1R) that has been developed for use in human brain imaging. …

[HTML][HTML] Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1/2 trial

…, RSN Fehrmann, BM Fine, SM Sanabria Bohórquez… - Nature Medicine, 2022 - nature.com
Immune checkpoint inhibitors (ICIs), by reinvigorating CD8 + T cell mediated immunity, have
revolutionized cancer therapy. Yet, the systemic CD8 + T cell distribution, a potential …

[18F]GTP1 (Genentech Tau Probe 1), a radioligand for detecting neurofibrillary tangle tau pathology in Alzheimer's disease

S Sanabria Bohórquez, J Marik, A Ogasawara… - European journal of …, 2019 - Springer
Objective Neurofibrillary tangles (NFTs), consisting of intracellular aggregates of the tau
protein, are a pathological hallmark of Alzheimer’s disease (AD). Here we report the …